C2I is very happy for our graduates and we wish them inspiration, success, and new scientific breakthroughs.

Nicoya develops innovative and accessible biosensor technology for in-depth characterization of biomolecular interactions. Alto, the world’s first digital high-throughput benchtop SPR instrument, is capable of accelerating drug discovery using a fraction of sample volume traditionally required for biomolecular interaction analyses. Alto helps biotechnology and pharmaceutical companies go-to-market faster with increased efficiency and success early in their product pipelines.

DeepCure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. Their vision is to use AI-driven discovery to create better molecules and faster cures for every disease-relevant protein target.

Fosun Pharma, a leading healthcare group in China, strives to be one of the first-class enterprises in the global mainstream healthcare market.

Cellens is pioneering in label-free cell analysis with a combination of high-resolution nanoscale imaging and proprietary machine learning.

Prolacta Bioscience discovers, develops, and delivers life-changing solutions for critically ill babies and other vulnerable patients. They achieve this through innovative human milk research and leadership in quality and safety.

Revela is helping women struggling with hair thinning with their products using ProCelinyl™, the first and only ingredient that directly supports your hair follicles. Existing solutions support increased blood flow, DHT inhibition, and overall nutrition and wellness in hopes that your body will produce healthier hair. ProCelinyl focuses its attention directly on your follicles to effectively reawaken your roots.

SynerK, Inc. is a biotechnology company engaged in the development of life changing treatment in the areas of cancer, inflammatory and rare diseases. SynerK utilizes antisense technology to specifically silence genes that are responsible for various diseases.

Dynamic Biosensors is a provider of instruments, consumables, and services in the field of analytical systems for the characterization of biomolecules and molecular interactions. Dynamic Biosensors commercializes switchSENSE® technology, a groundbreaking platform technology for the analysis of biomolecules with applications in R&D and drug development.

MarvelBiome, Inc. is a biopharmaceutical company with a vision of harnessing the power of microbes for treating various human diseases.

Gradiant delivers solutions that help to make a positive impact on both the economy and the environment. Their core focus is on solving the most complex water and wastewater challenges with innovative, sustainable solutions.

Frequency Therapeutics is a platform technology with an initial focus on chronic hearing loss, a potential $10B+ US market with no effective therapeutic solution. Other potential applications include gastrointestinal diseases and diabetes.

SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a portfolio of differentiated best-in-class therapeutics.

Nano-C started operations in 2001, and is a leader in the world of nano-structured carbon materials and chemicals.

SQZ Biotech is a company founded out of the Massachusetts Institute of Technology (MIT). At SQZ, they have developed a high-throughput platform - CellSqueeze - for simple and effective material delivery into cells.

Ankaa Therapeutics is a leader in developing targeted small molecule drugs for personalized therapy.

Snapdragon Chemistry is headquartered in Boston, MA and is a leading provider of flow chemistry solutions and services.

Rilas Technologies provides services in the areas of purification of small molecule drug candidates from early discovery through to clinical phases.

Mercury Therapeutics Inc is a biotechnology company based out of 2 Gill St, Woburn, Massachusetts, United States.

The Augusta founding laboratories have used cutting edge genetic technologies and shRNA screening methodologies to uncover the ROS receptor tyrosine kinase as a cancer survival gene.

Veraquel has developed a transformative technology for the synthesis of peptide drugs, applicable from discovery to large-scale manufacturing by enabling the parallel synthesis of purified peptides.

Aquilus Pharmaceuticals is a privately held biotechnology company specializing in the treatment and management of pain.

At RootPath Genomics, Inc., we have developed a number of proprietary technologies in molecular engineering and computational biology that promise to bring precision medicine to immunotherapy of cancer.

Material Answers LLC specializes in conceptualization and development of innovative polymer material systems for achieving focused performance targets. Material Answers also provides consulting and expert witness services in material science and engineering and chemical engineering.

KEMBIOTIX LLC offers customized solutions to meet their clients' business needs.

Anfiro™ is a water technology start-up addressing global freshwater scarcity.

Sequence with Accuracy SeqLL is an industry leading DNA and RNA sequencing service provider, particularly for single molecule sequencing data.

Science is at the core of everything Bambu Global does. They aim to improve the health of people and our planet with disruptive technologies that lie at the intersection of biology, chemistry, and physics–primarily involving the transformation of electromagnetic energy into remarkable color and light effects. Their technologies are on track to change a myriad of markets–lighting, tattoo, defense, life science, renewable energy, and safety markets.

Metalmark is on a mission to address challenges associated with air pollution and climate change by inventing novel materials that can decompose contaminants and improve energy efficiency.

Real Isolates investigates novel processing protocols for natural products.

ConsortiaTX, Inc. is a seed stage, pre-clinical bio-therapeutics company that emerged from research laboratories at Brigham & Women’s Hospital and Children’s Hospital in Boston. The company’s intellectual property around food allergies and the human gut microbiome is based on the work of Lynn Bry, M.D., Ph.D., Georg Gerber, M.D., Ph.D. (both at BWH), and Talal Chatilla, Ph.D. (at CHB) and others.